Tag: Australia

Institutional investors are returning to psychedelic medicine in force, with the sector raising more than US$1 billion in a single ...

For much of the past decade, Australia's medicinal cannabis industry has been defined by domestic growth. Companies raced to expand ...

Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...

Newly rebranded BLS Pharmaceuticals (ASX:BLS) has capped off a transformational financial year, reporting record revenue, profitability and operating cash flow ...

For much of the past decade, success in the cannabis and psychedelic sectors has been measured by one metric above ...

As psychedelic medicine edges closer to mainstream clinical practice, Europe is approaching a pivotal moment that could shape the sector ...

Canadian pharmaceutical manufacturer Optimi Health has completed a commercial export of GMP-grade psilocybin capsules to Australia under the Therapeutic Goods ...